{"protocolSection": {"identificationModule": {"nctId": "NCT03971539", "orgStudyIdInfo": {"id": "1371-0008"}, "secondaryIdInfos": [{"id": "2019-000805-60", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma", "officialTitle": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 894416 Versus Placebo in Male Patients With Asthma (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)."}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-07-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-10-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-10-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-05-20", "studyFirstSubmitQcDate": "2019-05-30", "studyFirstPostDateStruct": {"date": "2019-06-03", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-09-26", "resultsFirstSubmitQcDate": "2022-09-26", "resultsFirstPostDateStruct": {"date": "2023-08-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-09-26", "lastUpdatePostDateStruct": {"date": "2023-08-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens. Based on these, the primary trial objective is to assess safety and tolerability of BI 894416 at each dose.\n\nSecondary measures of interest are the geometric means of BI 894416 plasma AUC0-\u221e and Cmax after single dose in SRD part and AUC0-8 and Cmax after single dose as well as AUC\u03c4,ss and Cmax,ss after 7 days multiple dosing in MRD part. The objective is to assess the pharmacokinetics of BI 894416 following single and multiple administration."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 68, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SRD part: Placebo", "type": "PLACEBO_COMPARATOR", "description": "Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "interventionNames": ["Drug: Placebo"]}, {"label": "SRD part: 75 mg BI 894416", "type": "EXPERIMENTAL", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "interventionNames": ["Drug: BI 894416", "Drug: Placebo"]}, {"label": "SRD part: 125 mg BI 894416", "type": "EXPERIMENTAL", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "interventionNames": ["Drug: BI 894416"]}, {"label": "SRD part: 170 mg BI 894416", "type": "EXPERIMENTAL", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "interventionNames": ["Drug: BI 894416"]}, {"label": "MRD part: Placebo", "type": "PLACEBO_COMPARATOR", "description": "Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "interventionNames": ["Drug: Placebo"]}, {"label": "MRD part: 10 mg BI 894416", "type": "EXPERIMENTAL", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "interventionNames": ["Drug: BI 894416"]}, {"label": "MRD part: 25 mg BI 894416", "type": "EXPERIMENTAL", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "interventionNames": ["Drug: BI 894416"]}, {"label": "MRD part: 50 mg BI 894416", "type": "EXPERIMENTAL", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "interventionNames": ["Drug: BI 894416"]}, {"label": "MRD part: 60 mg BI 894416", "type": "EXPERIMENTAL", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "interventionNames": ["Drug: BI 894416"]}], "interventions": [{"type": "DRUG", "name": "BI 894416", "description": "BI 894416 film-coated tablet.", "armGroupLabels": ["MRD part: 10 mg BI 894416", "MRD part: 25 mg BI 894416", "MRD part: 50 mg BI 894416", "MRD part: 60 mg BI 894416", "SRD part: 125 mg BI 894416", "SRD part: 170 mg BI 894416", "SRD part: 75 mg BI 894416"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo film-coated tablet matching BI 894416.", "armGroupLabels": ["MRD part: Placebo", "SRD part: 75 mg BI 894416", "SRD part: Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Patients With Treatment-emergent Adverse Events Related to BI 894416", "description": "Percentage of patients with treatment-emergent adverse events (AEs) related to BI 894416.", "timeFrame": "From start of treatment till the end of trial, up to 30 days."}], "secondaryOutcomes": [{"measure": "AUC0-\u221e (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity) of BI 894416 (SRD Part)", "description": "AUC0-\u221e (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) of BI 894416 (single rising dose part).", "timeFrame": "3 hours before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72 and 96 hours following treatment."}, {"measure": "Cmax (Maximum Measured Concentration of the Analyte in Plasma) of BI 894416 (SRD Part)", "description": "Cmax (maximum measured concentration of the analyte in plasma) of BI 894416 (single rising dose part).", "timeFrame": "3 hours before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72 and 96 hours following treatment."}, {"measure": "AUC0-8 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 8 Hours) of BI 894416 After the First Dose (MRD Part)", "description": "AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 8 hours) of BI 894416 after the first dose (Multiple rising dose part).", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours following first dose (day 1)."}, {"measure": "Cmax (Maximum Measured Concentration of the Analyte in Plasma) of BI 894416 After the First Dose (MRD Part)", "description": "Cmax (maximum measured concentration of the analyte in plasma) of BI 894416 after the first dose (Multiple rising dose part).", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 23.92 hours following first dose (day 1)."}, {"measure": "AUCtau,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State) of BI 894416 After the Last Dose (MRD Part)", "description": "AUCtau,ss (area under the concentration-time curve of the analyte in plasma at steady state) of BI 894416 after the last dose (Multiple rising dose part).", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours following last dose (day 9)."}, {"measure": "Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State) of BI 894416 After the Last Dose (MRD Part)", "description": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state) of BI 894416 after the last dose (Multiple rising dose part).", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours following last dose (day 9)."}, {"measure": "Difference From Baseline in Airway Resistance (RAW) After 7 Days of Treatment (MRD Part)", "description": "Difference in airway resistance (RAW) from baseline (measured on day 1) to day 9, after 7 days (day 2-8) of t.i.d. (three times daily) treatment.", "timeFrame": "Up to 9 days."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. Medication washout and medication restrictions according to protocol are allowed only after informed consent is obtained.\n* Male patients aged at least 18 years but not more than 55 years at the time of informed consent.\n* Men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.\n* Pre-bronchodilator clinic measured FEV1 of \u2265 70% of predicted normal at the screening visit (Visit 1). Calculations will be based on Global Lung Function Initiative (GLI) formula\n* A diagnosis of asthma, diagnosed by a physician.\n* Patients should be non-smokers or ex-smokers who stopped smoking at least 12 weeks prior to screening and are expected to be able to not smoke for the duration of the study.\n* Patients must be able to perform all trial related procedures including pulmonary function tests, nasal brushings.\n* BMI of 18.5 to 32 kg/m2 (incl.)\n* For MRD part: Patients are allowed to be on stable inhaled low dose corticosteroid (please refer to GINA guidelines) for at least 4 weeks prior to screening.\n\nExclusion Criteria:\n\n* Any finding in the medical examination (including BP, PR, echocardiography and echocardiography stress test or ECG and including the neurological examination) is deviating from normal and judged as clinically relevant by the investigator\n* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm\n* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n* Any evidence of a concomitant disease judged as clinically relevant by the investigator\n* Gastrointestinal, hepatic, renal, respiratory, cardiovascular (stress), metabolic, immunological or hormonal disorders\n* Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)\n* Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders\n* History of relevant orthostatic hypotension, fainting spells, or blackouts\n* Chronic or relevant acute infections\n* History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)\n* Use of drugs within 30 days prior to administration of trial medication that might reasonably influence the results of the trial (incl. QT/QTc interval prolongation)\n* Participation in another trial where an investigational drug other than BI 894416 has been administered within 60 days or 5 half-lives (whichever is greater) prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug. In case of planned participation in the MRD part in this trial the previous participation in one dose group of the SRD part is allowed if BI 894416 has been administered more than 21 days prior to planned administration of BI 894416 in the MRD part. (Participation in an SRD dose group after the patient has participated in the MRD part is not allowed.)\n* Alcohol abuse (consumption of more than 24 g per day)\n* Drug abuse or positive drug screening\n* Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial\n* Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial\n* Inability to comply with dietary regimen of trial site\n* A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening\n* A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)\n* Patient unable or unwilling to comply with study requirements, or has a condition that would not allow safe participation in the study\n* History of relevant neurological disorder affecting the peripheral or central nervous system (this includes, but is not limited to: stroke, epilepsy, inflammatory or atrophic diseases affecting the nervous system, cluster headache or any cancer of the nervous system)\n* History of immunological disease except allergy not relevant to the trial (such as mild hayfever or dust mite allergy) and except asthma in childhood or adolescence\n* History of cancer (other than successfully treated basal cell carcinoma)\n* Use of any drug that could reasonably inhibit platelet aggregation or coagulation (e.g. acetylsalicylic acid) within 10 days prior to administration of trial medication, or planned use during the trial or within 7 days after last dose of trial medication.\n* Further exclusion criteria apply.", "healthyVolunteers": false, "sex": "MALE", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Fraunhofer ITEM", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://www.mystudywindow.com"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:\n\n1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer-ingelheim.com/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.", "recruitmentDetails": "The trial was randomised, placebo-controlled within groups, and single blinded. The trial consisted of a single rising dose (SRD) and a multiple rising dose (MRD) part. Last follow-up visit occurred between 14 and 16 days after the single dose for the SRD part and between day 14 and 21 days after the last dose for the MRD part.", "groups": [{"id": "FG000", "title": "SRD Part: Placebo", "description": "Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "FG001", "title": "SRD Part: 75 mg BI 894416", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "FG002", "title": "SRD Part: 125 mg BI 894416", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "FG003", "title": "SRD Part: 170 mg BI 894416", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "FG004", "title": "MRD Part: Placebo", "description": "Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "FG005", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "FG006", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "FG007", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "FG008", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "7"}, {"groupId": "FG006", "numSubjects": "8"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "7"}, {"groupId": "FG006", "numSubjects": "8"}, {"groupId": "FG007", "numSubjects": "8"}, {"groupId": "FG008", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set (TS): the TS includes all patients who were randomised and treated with at least one dose of trial medication. The treatment assignment was determined based on the 1st treatment the patient received.", "groups": [{"id": "BG000", "title": "SRD Part: Placebo", "description": "Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "BG001", "title": "SRD Part: 75 mg BI 894416", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "BG002", "title": "SRD Part: 125 mg BI 894416", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "BG003", "title": "SRD Part: 170 mg BI 894416", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "BG004", "title": "MRD Part: Placebo", "description": "Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "BG005", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "BG006", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "BG007", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "BG008", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "BG009", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "7"}, {"groupId": "BG006", "value": "8"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "8"}, {"groupId": "BG009", "value": "68"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.7", "spread": "12.3"}, {"groupId": "BG001", "value": "30.6", "spread": "7.2"}, {"groupId": "BG002", "value": "27.1", "spread": "7.5"}, {"groupId": "BG003", "value": "29.3", "spread": "9.3"}, {"groupId": "BG004", "value": "26.1", "spread": "4.4"}, {"groupId": "BG005", "value": "32.7", "spread": "11.2"}, {"groupId": "BG006", "value": "29.9", "spread": "10.6"}, {"groupId": "BG007", "value": "30.9", "spread": "9.0"}, {"groupId": "BG008", "value": "28.9", "spread": "9.0"}, {"groupId": "BG009", "value": "30.2", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "7"}, {"groupId": "BG006", "value": "8"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "8"}, {"groupId": "BG009", "value": "68"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "2"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "7"}, {"groupId": "BG006", "value": "7"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "8"}, {"groupId": "BG009", "value": "66"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "1"}, {"groupId": "BG009", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "7"}, {"groupId": "BG006", "value": "7"}, {"groupId": "BG007", "value": "8"}, {"groupId": "BG008", "value": "7"}, {"groupId": "BG009", "value": "65"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Patients With Treatment-emergent Adverse Events Related to BI 894416", "description": "Percentage of patients with treatment-emergent adverse events (AEs) related to BI 894416.", "populationDescription": "Treated set (TS): the TS includes all patients who were randomised and treated with at least one dose of trial medication. The treatment assignment was determined based on the 1st treatment the patient received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "From start of treatment till the end of trial, up to 30 days.", "groups": [{"id": "OG000", "title": "SRD Part: Placebo", "description": "Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG001", "title": "SRD Part: 75 mg BI 894416", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG002", "title": "SRD Part: 125 mg BI 894416", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG003", "title": "SRD Part: 170 mg BI 894416", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG004", "title": "MRD Part: Placebo", "description": "Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG005", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG006", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG007", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG008", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG009", "title": "SRD Part: Total BI 894416", "description": "Single rising dose (SRD) part, total of all subjects treated with BI 894416 (75 mg, 125 mg and 170 mg)."}, {"id": "OG010", "title": "SRD Part: Total (BI 894416 and Placebo)", "description": "Single rising dose (SRD) part, total of all subjects in SRD part (75 mg, 125 mg 170 mg and placebo)."}, {"id": "OG011", "title": "MRD Part: Total BI 894416", "description": "Multiple rising dose (MRD) part, total of all subjects treated with BI 894416 (10 mg, 25 mg, 50 mg and 60 mg)."}, {"id": "OG012", "title": "MRD Part: Total (BI 894416 and Placebo)", "description": "Multiple rising dose (MRD) part, total of all subjects in MRD part (10 mg, 25 mg, 50 mg, 60 mg and placebo)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}, {"groupId": "OG004", "value": "8"}, {"groupId": "OG005", "value": "7"}, {"groupId": "OG006", "value": "8"}, {"groupId": "OG007", "value": "8"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "23"}, {"groupId": "OG010", "value": "29"}, {"groupId": "OG011", "value": "31"}, {"groupId": "OG012", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "28.6"}, {"groupId": "OG002", "value": "37.5"}, {"groupId": "OG003", "value": "62.5"}, {"groupId": "OG004", "value": "0.0"}, {"groupId": "OG005", "value": "28.6"}, {"groupId": "OG006", "value": "0.0"}, {"groupId": "OG007", "value": "25.0"}, {"groupId": "OG008", "value": "25.0"}, {"groupId": "OG009", "value": "43.5"}, {"groupId": "OG010", "value": "34.5"}, {"groupId": "OG011", "value": "19.4"}, {"groupId": "OG012", "value": "15.4"}]}]}]}, {"type": "SECONDARY", "title": "AUC0-\u221e (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity) of BI 894416 (SRD Part)", "description": "AUC0-\u221e (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) of BI 894416 (single rising dose part).", "populationDescription": "Pharmacokinetic set (PKS): the PKS includes all patients in the TS who provided at least one pharmacokinetic endpoint that was not excluded due to a protocol deviation relevant to the evaluation of pharmacokinetics, or due to pharmacokinetic non-evaluability.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles*hours/liter", "timeFrame": "3 hours before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72 and 96 hours following treatment.", "groups": [{"id": "OG000", "title": "SRD Part: 75 mg BI 894416", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG001", "title": "SRD Part: 125 mg BI 894416", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG002", "title": "SRD Part: 170 mg BI 894416", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15900", "spread": "41.5"}, {"groupId": "OG001", "value": "26400", "spread": "30.0"}, {"groupId": "OG002", "value": "32500", "spread": "21.9"}]}]}]}, {"type": "SECONDARY", "title": "Cmax (Maximum Measured Concentration of the Analyte in Plasma) of BI 894416 (SRD Part)", "description": "Cmax (maximum measured concentration of the analyte in plasma) of BI 894416 (single rising dose part).", "populationDescription": "Pharmacokinetic set (PKS): the PKS includes all patients in the TS who provided at least one pharmacokinetic endpoint that was not excluded due to a protocol deviation relevant to the evaluation of pharmacokinetics, or due to pharmacokinetic non-evaluability.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles/liter", "timeFrame": "3 hours before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72 and 96 hours following treatment.", "groups": [{"id": "OG000", "title": "SRD Part: 75 mg BI 894416", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG001", "title": "SRD Part: 125 mg BI 894416", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}, {"id": "OG002", "title": "SRD Part: 170 mg BI 894416", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2340", "spread": "29.7"}, {"groupId": "OG001", "value": "4240", "spread": "25.3"}, {"groupId": "OG002", "value": "5280", "spread": "24.3"}]}]}]}, {"type": "SECONDARY", "title": "AUC0-8 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 8 Hours) of BI 894416 After the First Dose (MRD Part)", "description": "AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 8 hours) of BI 894416 after the first dose (Multiple rising dose part).", "populationDescription": "Pharmacokinetic set (PKS): the PKS includes all patients in the TS who provided at least one pharmacokinetic endpoint that was not excluded due to a protocol deviation relevant to the evaluation of pharmacokinetics, or due to pharmacokinetic non-evaluability.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles*hours/liter", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours following first dose (day 1).", "groups": [{"id": "OG000", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG001", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG002", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG003", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "992", "spread": "28.1"}, {"groupId": "OG001", "value": "3130", "spread": "9.62"}, {"groupId": "OG002", "value": "4320", "spread": "28.4"}, {"groupId": "OG003", "value": "7310", "spread": "35.1"}]}]}]}, {"type": "SECONDARY", "title": "Cmax (Maximum Measured Concentration of the Analyte in Plasma) of BI 894416 After the First Dose (MRD Part)", "description": "Cmax (maximum measured concentration of the analyte in plasma) of BI 894416 after the first dose (Multiple rising dose part).", "populationDescription": "Pharmacokinetic set (PKS): the PKS includes all patients in the TS who provided at least one pharmacokinetic endpoint that was not excluded due to a protocol deviation relevant to the evaluation of pharmacokinetics, or due to pharmacokinetic non-evaluability.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles/liter", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 23.92 hours following first dose (day 1).", "groups": [{"id": "OG000", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG001", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG002", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG003", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "239", "spread": "31.6"}, {"groupId": "OG001", "value": "704", "spread": "20.6"}, {"groupId": "OG002", "value": "1170", "spread": "40.0"}, {"groupId": "OG003", "value": "1730", "spread": "49.5"}]}]}]}, {"type": "SECONDARY", "title": "AUCtau,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State) of BI 894416 After the Last Dose (MRD Part)", "description": "AUCtau,ss (area under the concentration-time curve of the analyte in plasma at steady state) of BI 894416 after the last dose (Multiple rising dose part).", "populationDescription": "Pharmacokinetic set (PKS): the PKS includes all patients in the TS who provided at least one pharmacokinetic endpoint that was not excluded due to a protocol deviation relevant to the evaluation of pharmacokinetics, or due to pharmacokinetic non-evaluability.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles*hours/liter", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours following last dose (day 9).", "groups": [{"id": "OG000", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG001", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG002", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG003", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1460", "spread": "48.6"}, {"groupId": "OG001", "value": "4770", "spread": "19.7"}, {"groupId": "OG002", "value": "5420", "spread": "33.2"}, {"groupId": "OG003", "value": "9400", "spread": "30.6"}]}]}]}, {"type": "SECONDARY", "title": "Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State) of BI 894416 After the Last Dose (MRD Part)", "description": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state) of BI 894416 after the last dose (Multiple rising dose part).", "populationDescription": "Pharmacokinetic set (PKS): the PKS includes all patients in the TS who provided at least one pharmacokinetic endpoint that was not excluded due to a protocol deviation relevant to the evaluation of pharmacokinetics, or due to pharmacokinetic non-evaluability.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanomoles/liter", "timeFrame": "5 minutes before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 96 hours following last dose (day 9).", "groups": [{"id": "OG000", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG001", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG002", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG003", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "299", "spread": "42.7"}, {"groupId": "OG001", "value": "985", "spread": "19.4"}, {"groupId": "OG002", "value": "1290", "spread": "52.1"}, {"groupId": "OG003", "value": "2130", "spread": "30.3"}]}]}]}, {"type": "SECONDARY", "title": "Difference From Baseline in Airway Resistance (RAW) After 7 Days of Treatment (MRD Part)", "description": "Difference in airway resistance (RAW) from baseline (measured on day 1) to day 9, after 7 days (day 2-8) of t.i.d. (three times daily) treatment.", "populationDescription": "Treated set (TS): the TS includes all patients who were randomised and treated with at least one dose of trial medication. The treatment assignment was determined based on the 1st treatment the patient received. The TS was used for safety analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kilopascal/liter/second", "timeFrame": "Up to 9 days.", "groups": [{"id": "OG000", "title": "MRD Part: Placebo", "description": "Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG001", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG002", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG003", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}, {"id": "OG004", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "7"}, {"groupId": "OG004", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.052", "spread": "0.086"}, {"groupId": "OG001", "value": "0.069", "spread": "0.026"}, {"groupId": "OG002", "value": "0.041", "spread": "0.038"}, {"groupId": "OG003", "value": "0.041", "spread": "0.066"}, {"groupId": "OG004", "value": "0.000", "spread": "0.082"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From start of treatment till the end of trial, up to 30 days.", "description": "Treated set (TS): the TS includes all patients who were randomised and treated with at least one dose of trial medication. The treatment assignment was determined based on the 1st treatment the patient received.", "eventGroups": [{"id": "EG000", "title": "SRD Part: Placebo", "description": "Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 1, "otherNumAtRisk": 6}, {"id": "EG001", "title": "SRD Part: 75 mg BI 894416", "description": "Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 5, "otherNumAtRisk": 7}, {"id": "EG002", "title": "SRD Part: 125 mg BI 894416", "description": "Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 5, "otherNumAtRisk": 8}, {"id": "EG003", "title": "SRD Part: 170 mg BI 894416", "description": "Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 7, "otherNumAtRisk": 8}, {"id": "EG004", "title": "MRD Part: Placebo", "description": "Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 6, "otherNumAtRisk": 8}, {"id": "EG005", "title": "MRD Part: 10 mg BI 894416", "description": "Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 5, "otherNumAtRisk": 7}, {"id": "EG006", "title": "MRD Part: 25 mg BI 894416", "description": "Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 7, "otherNumAtRisk": 8}, {"id": "EG007", "title": "MRD Part: 50 mg BI 894416", "description": "Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 7, "otherNumAtRisk": 8}, {"id": "EG008", "title": "MRD Part: 60 mg BI 894416", "description": "Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 5, "otherNumAtRisk": 8}, {"id": "EG009", "title": "SRD Part: Total BI 894416", "description": "Single rising dose (SRD) part, total of all subjects treated with BI 894416 (75 mg, 125 mg and 170 mg).", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 17, "otherNumAtRisk": 23}, {"id": "EG010", "title": "SRD Part: Total (BI 894416 and Placebo)", "description": "Single rising dose (SRD) part, total of all subjects in SRD part (75 mg, 125 mg 170 mg and placebo).", "deathsNumAffected": 0, "deathsNumAtRisk": 29, "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 18, "otherNumAtRisk": 29}, {"id": "EG011", "title": "MRD Part: Total BI 894416", "description": "Multiple rising dose (MRD) part, total of all subjects treated with BI 894416 (10 mg, 25 mg, 50 mg and 60 mg).", "deathsNumAffected": 0, "deathsNumAtRisk": 31, "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 24, "otherNumAtRisk": 31}, {"id": "EG012", "title": "MRD Part: Total (BI 894416 and Placebo)", "description": "Multiple rising dose (MRD) part, total of all subjects in MRD part (10 mg, 25 mg, 50 mg, 60 mg and placebo).", "deathsNumAffected": 0, "deathsNumAtRisk": 39, "seriousNumAffected": 0, "seriousNumAtRisk": 39, "otherNumAffected": 30, "otherNumAtRisk": 39}, {"id": "EG013", "title": "Total BI 894416", "description": "All subjects treated with BI 894416 in either the single rising dose or multiple rising dose part.", "deathsNumAffected": 0, "deathsNumAtRisk": 54, "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 41, "otherNumAtRisk": 54}, {"id": "EG014", "title": "Total", "description": "All subjects in the study.", "deathsNumAffected": 0, "deathsNumAtRisk": 68, "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 48, "otherNumAtRisk": 68}], "otherEvents": [{"term": "Neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Normochromic normocytic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Conjunctival haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Abdominal pain lower", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Faeces soft", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 3, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 3, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 4, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 3, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 4, "numAtRisk": 68}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 3, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 3, "numAtRisk": 68}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Medical device site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Sluggishness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Mite allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Eyelid infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 4, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 4, "numAtRisk": 68}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Otitis externa", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Burns second degree", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Skin injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 3, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 4, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 4, "numAtRisk": 68}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Head discomfort", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 3, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 13, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 13, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 7, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 10, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 20, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 23, "numAtRisk": 68}]}, {"term": "Nerve compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Tension headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Anxiety disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Bladder pain", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Micturition urgency", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 2, "numAtRisk": 68}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 7}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 68}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The planned last two dose level in the single rising dose (SRD) part and the last dose in the multiple rising dose (MRD) part were not used as the predicted exposure exceeded the limits predefined in the clinical trial protocol."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-10-14", "uploadDate": "2022-09-09T05:01", "filename": "Prot_000.pdf", "size": 1024351}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2021-02-10", "uploadDate": "2022-09-09T05:01", "filename": "SAP_001.pdf", "size": 302044}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}